XML 62 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8
OPERATING SEGMENT AND GEOGRAPHIC INFORMATION
 6 Months Ended
Jun. 30, 2014
Segment Reporting [Abstract]  
Operating Segment And Geographic Information
OPERATING SEGMENT AND GEOGRAPHIC INFORMATION
Our chief operating decision-maker is our Chief Executive Officer, who regularly evaluates our performance based on net sales and net loss before taxes. The preparation of this segment analysis requires management to make estimates and assumptions around expenses below the gross profit level. While we believe the segment information to be directionally correct, actual results could differ from the estimates and assumptions used in preparing this information.
We have two complementary reportable operating segments, Laboratory Services and Genetic Assays and Platforms.
 
Segment information for the three months ended June 30, 2014 and 2013 is as follows: 
 
Dollars in Thousands
 
Three Months Ended June 30, 2014
 
Laboratory Services
 
Genetic Assays
and Platforms
 
Total
Net Sales
$
3,843

 
$
2,921

 
$
6,764

Gross Profit
1,490

 
903

 
2,393

Net Loss before Taxes
(3,277
)
 
(624
)
 
(3,901
)
Income Tax Expense (Benefit)
40

 
(48
)
 
(8
)
Net Loss
$
(3,317
)
 
$
(576
)
 
$
(3,893
)
Depreciation/Amortization
$
438

 
$
50

 
$
488

Interest Expense, net
$
83

 
$
63

 
$
146

 
 
 
 
 
 
 
June 30, 2014
Total Assets
$
23,370

 
$
7,721

 
$
31,091


 
 
 
 
 
 
 
Dollars in Thousands
 
Three Months Ended June 30, 2013
 
Laboratory Services
 
Genetic Assays
and Platforms
 
Total
Net Sales
$
4,012

 
$
3,294

 
$
7,306

Gross Profit
1,853

 
1,120

 
2,973

Net Loss before Taxes
(2,181
)
 
(692
)
 
(2,873
)
Income Tax Expense
—

 
(6
)
 
(6
)
Net Loss
$
(2,181
)
 
$
(686
)
 
$
(2,867
)
Depreciation/Amortization
$
646

 
$
41

 
$
687

Interest Expense, net
$
84

 
$
67

 
$
151

 
 
 
 
 
 
 
June 30, 2013
Total Assets
$
27,834

 
$
11,529

 
$
39,363


Segment information for the six months ended June 30, 2014 and 2013 is as follows:

 
Dollars in Thousands
 
Six Months Ended June 30, 2014
 
Laboratory Services
 
Genetic Assays
and Platforms
 
Total
Net Sales
$
7,531

 
$
5,484

 
$
13,015

Gross Profit
3,122

 
1,765

 
4,887

Net Loss before Taxes
(6,261
)
 
(1,311
)
 
(7,572
)
Income Tax Expense (Benefit)
549

 
(52
)
 
497

Net Loss
$
(6,810
)
 
$
(1,259
)
 
$
(8,069
)
Depreciation/Amortization
$
878

 
$
103

 
$
981

Interest Expense, net
$
190

 
$
138

 
$
328

 
 
 
 
 
 

 
Dollars in Thousands
 
Six Months Ended June 30, 2013
 
Laboratory Services
 
Genetic Assays
and Platforms
 
Total
Net Sales
$
8,439

 
$
6,241

 
$
14,680

Gross Profit
4,046

 
2,182

 
6,228

Net Loss before Taxes
(5,267
)
 
(1,127
)
 
(6,394
)
Income Tax Expense (Benefit)
—

 
60

 
60

Net Loss
$
(5,267
)
 
$
(1,187
)
 
$
(6,454
)
Depreciation/Amortization
$
1,209

 
$
222

 
$
1,431

Interest Expense, net
$
219

 
$
85

 
$
304

 
 
 
 
 
 



Net sales for the three and six months ended June 30, 2014 and 2013 by country were as follows:
 
 
Dollars in Thousands
 
Dollars in Thousands
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2014
 
2013
 
2014
 
2013
United States
$
4,870

 
$
5,797

 
$
9,633

 
$
11,146

Italy
337

 
372

 
722

 
827

All Other Countries
1,557

 
1,137

 
2,660

 
2,707

Total
$
6,764

 
$
7,306

 
$
13,015

 
$
14,680


Other than the countries specifically identified above, no other country individually accounted for more than 5% of total net sales.

Approximately 99% of our long-lived assets are located within the United States.